Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06666790 · ClinicalTrials.gov registry record · NA
DermaSensor Postmarket Surveillance Study
A NA study of Melanoma (Skin), sponsored by DermaSensor.
- Recruiting
- Registry status
- NA
- Development phase
- 396
- Enrollment target
- 2
- Study locations
NCT06666790: Recruiting NA study of Melanoma (Skin), sponsored by DermaSensor.
NCT06666790 is a NA study of Melanoma (Skin) that is actively recruiting participants, run by DermaSensor. The registered enrollment target is 396 participants, above the 124-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (219% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06666790, a NA study of Melanoma (Skin), is actively recruiting participants, sponsored by DermaSensor.
- RECRUITING
- Registry status
- NA
- Development phase
- 396 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective of this study is to evaluate the sensitivity of the DermaSensor device and Investigators when used on skin lesions concerning for melanoma.
Conditions Studied
Interventions
- DEVICE Scan with elastic scattering spectroscopy device to assess risk of malignancy
Study Locations (2)
Florida
- Velocity - New Smyrna Beach
North Carolina
- West Clinical Research - Morehead City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 396 participants |
| Start Date | 2024-10-08 |
| Est. Completion | 2027-09-10 |
| Phase | NA |
What NCT06666790 shows while recruiting
NCT06666790 is an interventional study that assigns participants to a tested intervention. The registered 396 participants enrollment target is mid-sized for trials with a published cap, above the 124-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (219% higher).
The record links to 1 condition, with Melanoma (Skin) appearing as the primary indexed condition, and to 1 intervention - of which Scan with elastic scattering spectroscopy device to assess risk of malignancy is the first listed.
NCT06666790 reports a single indexed study location in Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06666790 about?
NCT06666790 is a clinical study titled "DermaSensor Postmarket Surveillance Study". The objective of this study is to evaluate the sensitivity of the DermaSensor device and Investigators when used on skin lesions concerning for melanoma.
What is the current status of trial NCT06666790?
This trial is currently recruiting. It is a NA study. The enrollment target is 396 participants. The study started on 2024-10-08. Estimated completion is 2027-09-10.
What conditions does trial NCT06666790 study?
This clinical trial studies the following conditions: Melanoma (Skin).
What interventions are being tested in trial NCT06666790?
The interventions under investigation include: Scan with elastic scattering spectroscopy device to assess risk of malignancy (DEVICE).
Who is sponsoring clinical trial NCT06666790?
This trial is sponsored by DermaSensor, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06666790 being conducted?
This trial has 2 study locations across Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma (Skin)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06666790's enrollment target sits among peer trials
396 4th of 30 higher than 27 of 30 other Melanoma (Skin) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma (Skin) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rural Adult and Youth Sun Protection Study
RECRUITING · NA
-
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
RECRUITING · NA
-
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
RECRUITING · Phase 2
-
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
RECRUITING · Phase 1
-
Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
RECRUITING
-
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05633615 · 396 participants · Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06227910 · 396 participants · Phase 3
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- NCT06545331 · 396 participants · Phase 1
Study of XB010 in Subjects With Solid Tumors
- NCT00601939 · 397 participants · NA
Effectiveness of Empowerment Group Sessions for Treating Suicidal African American Women in Abusive Relationships
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI